The Centre for Research on Eating Disorders at Oxford (CREDO)
The three leading treatments for adults with eating disorders were developed at CREDO
All three treatments have been strongly endorsed by NICE (2004, 2017)
CREDO is developing a direct-to-public digital treatment for binge eating (CBTe)
For more information about CREDO and its work go to credo-oxford.com
CREDO was established in 1981. It is funded by the Wellcome Trust. The main focus of its research is on the treatment of eating disorders. More recently, it has also developed methods to facilitate the dissemination of effective psychological interventions. It is in the process of creating a digital treatment for recurrent binge eating (CBTe).
CREDO developed the three leading treatments for adults with eating disorders, all of which have been endorsed by NICE: cognitive behaviour therapy for bulimia nervosa (NICE, 2004); enhanced CBT for eating disorders, CBT-E (NICE, 2017); and guided self-help (NICE, 2017).
CREDO is currently developing a direct-to-public digital treatment for people with recurrent binge eating (CBTe).
CREDO developed the most widely used measures of eating disorder features: the Eating Disorder Examination interview (EDE), the Eating Disorder Examination questionnaire (EDE-Q), and the Clinical Impairment Assessment (CIA).
Recently, CREDO devised a scalable way of training clinicians to deliver evidence-based psychological treatments. This has proved popular and effective. It provides a means of training almost unlimited numbers of geographically dispersed therapists at low cost, thereby overcoming several obstacles to the dissemination of psychological treatments.
CREDO has close collaborative links with Professor Vikram Patel's team in India. It has assisted in the development of two psychological treatments, one for depression and the other for harmful drinking. Both are delivered by lay counsellors and both have proved remarkably effective given their low intensity.
CREDO is working with Professor Ilina Singh on the ethical and regulatory ramifications of autonomous, direct-to-public, digital treatments. This is uncharted territory.